Bluestar Genomics Commercializes Pancreatic Cancer Test
Bluestar Genomics has announced its U.S. and international commercialization of a test for early detection of pancreatic cancer.
Category: Pancreatic
Pancreatic
Latest
Pancreatic
Latest
Liquid Biopsy Test Detects Pancreatic Cancer Signal
Bluestar Genomics’ liquid biopsy test can detect a pancreatic cancer signal in people across various age groups and in patients with new-onset diabetes.
Pancreatic
Latest
Sysmex Inostics’ Liquid Biopsy Testing Aids Pancreatic Cancer Management
cfDNA-based liquid biopsy analysis of KRAS mutations using OncoBEAM technology can assist in the prognosis determination and management of PDAC patients.
US Preventive Services Task Force Issues Final Recommendation on BRCA-Related Cancer Prevention
Some women may benefit from risk assessment, counseling, and testing for rare genetic mutations, says USPSTF.
Read More
BRACAnalysis CDx Identifies Patients with Metastatic Pancreatic Cancer Who Benefit from Treatment with Lynparza
Updated guidelines from the National Comprehensive Cancer Network recommend genetic testing for all patients with pancreatic cancer.
Read More
Biodesix and Immodulon Announce Research Collaboration for Pancreatic Cancer Treatment
The partnership will focus on analysis of the circulating proteome of advanced pancreatic cancer patients, using the Biodesix Diagnostic Cortex machine-learning platform.
Read More
Researchers Advance Method for Characterizing Pancreatic Cancer
An Okayama University study reports the utility of identifying PD-L1 status at the time of diagnosing pancreatic cancer and demonstrates that fine-needle aspiration can be useful in facilitating such diagnoses.
Read More
BRACAnalysis CDx Test Planned as Companion Diagnostic in Pancreactic Cancer
Early results suggest the test can help expand the population of patients who can benefit from BRCA testing.
Read MoreImmunovia to Develop Blood-Based Biomarker Tests for Rheumatoid Arthritis
In a recent study, the company’s IMMray biomarker signatures achieved accuracy greater than 90% when diagnosing CCP-negative rheumatoid arthritis patients compared to healthy controls.
Read More
Biomarker Test Accurately Detects Early-Stage Pancreatic Cancer
Immunovia’s serum biomarker microarray detects pancreatic cancer in the early stages of development with 96% accuracy.
Read More
Linköping University Hospital Joins Clinical Study for Early Detection of Pancreatic Cancer
The PanFAM-1 study is designed to validate Immunovia’s IMMray PanCan-d assay, the first blood-based test for early detection of pancreatic cancer.
Read More
Spanish Hospital Joins World’s Largest Study of Risk for Familial Pancreatic Cancer
Designed to validate Immunovia’s blood-based test for familial pancreatic cancer risk, the study will analyze more than 1,000 individuals across sites in the United States and Europe.
Read More
Ortho Clinical Diagnostics Launches C-Peptide Assay
Ortho Clinical Diagnostics has launched the Vitros Immunodiagnostic Products C-Peptide reagent pack and calibrators, which broadens the company’s menu of tests for all aspects of diabetes and other pancreatic disorders.
Read MoreThermo Fisher Scientific Expands Its Liquid Biopsy and Immunooncology Portfolio
Thermo Fisher Scientific has expanded its Oncomine portfolio with new assays for liquid biopsy and immunooncology.
Read More
Delivering on the Promise of NGS for Clinical Diagnostics
Presenting an evaluation of the GeneReader next-generation sequencing (NGS) system, the article assesses the performance of the system in comparison with an alternative NGS technology.
Read More
January/February 2018 Product Spotlight: Laboratory Reagents and Consumables
This month’s issue features laboratory reagents and consumables from such companies as Audit Microcontrols, Bio-rad Laboratories, and Diasorin Molecular.
Read MoreStudy Supports Use of DiviTum for Evaluation of Pancreatic Cancer
The proof-of-concept study, done in collaboration with researchers at the University of Heidelberg, provides evidence for using DiviTum as a dynamic biomarker before and during therapy to give important answers regarding prognosis and therapy efficacy.
Read More
Roche Releases Tissue Dissection Instrument
The instrument utilizes an automated digitally assisted process to isolate clinically relevant cells from formalin-fixed paraffin-embedded tissue slides.
Read More